SU1369039A1 - Method of simulating compensation of diabetes - Google Patents
Method of simulating compensation of diabetes Download PDFInfo
- Publication number
- SU1369039A1 SU1369039A1 SU823474670A SU3474670A SU1369039A1 SU 1369039 A1 SU1369039 A1 SU 1369039A1 SU 823474670 A SU823474670 A SU 823474670A SU 3474670 A SU3474670 A SU 3474670A SU 1369039 A1 SU1369039 A1 SU 1369039A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- compensation
- diabetes
- anterior chamber
- eye
- transplantation
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 8
- 238000000034 method Methods 0.000 title claims description 5
- 210000002159 anterior chamber Anatomy 0.000 claims abstract description 8
- 238000002054 transplantation Methods 0.000 claims abstract description 6
- 210000000496 pancreas Anatomy 0.000 claims abstract description 4
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 3
- 239000012528 membrane Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Изобретение относитс к экспериментальной медицине. Цель изобретени - предупреждение отторжени трансплантата. Провод т пересадку хвостовой части эмбриональной поджелудочной железы на радужную оболочку передней камеры глаза крысы. Компенсаци сахарного диабета отмечалась на 2-й неделе после трансплантации.This invention relates to experimental medicine. The purpose of the invention is the prevention of graft rejection. The tail of the embryonic pancreas is transplanted to the iris of the anterior chamber of the rat eye. Compensation of diabetes mellitus was observed on the 2nd week after transplantation.
Description
ооoo
О5O5
со о соwith about with
соwith
Изобретение относитс к экспсрименталь ной медицине и может быть использовано дл разработки способов лечени сахарного диабета.The invention relates to experimental medicine and can be used to develop methods for treating diabetes mellitus.
Целью изобретени вл етс предупреж- дение отторжени трансплантата путем использовани дл трансплантации передней камеры глаза, отделенной от иммунной системы гематоофтальмологическим барьером.The aim of the invention is to prevent transplant rejection by using for the transplantation of the anterior chamber of the eye, which is separated from the immune system by the blood-brain barrier.
Пример. Пересадку ткани провод т в стерильных услови х. Крысе-донору с 17 дневной беременностью под нембуталовым наркозом делают кесарево сечение (выиимают эмбрионы, промывают в дистиллированной воде и спирте и перенос т в стерильный раствор Игла). Поджелудочную железу у эмбрионов выдел ют под стереомикроско- пом. С хвостового конца железы отрезают 1-2 кусочка объемом 0,8-1,0 мм каждый и перенос т в чашку Петри со стерильным раствором Игла.Example. The graft was made under sterile conditions. A donor rat with 17-day gestation is under caesarean section under Nembutal anesthesia (extracts the embryos, washed in distilled water and alcohol, and transferred to a sterile Needle solution). The pancreas from embryos is isolated under stereo microscopy. From the tail end of the gland, 1-2 pieces of a volume of 0.8-1.0 mm each are cut off and transferred to a Petri dish with a sterile needle solution.
Крысам-реципиентам на глаз нанос т каплю 0,1%-иого раствора атропина и каплю 0,5%-ного раствора новокан Гд. Трансплантацию провод т мод эфирным наркозом. При помощи туберкулинового шприца с винтовой подачей, на который надет стекл н- ный наконечник (внх ренний диаметр 0,8- (l ,0 мм) трансплантат берут из чашки Петри и ввод т через разрез в роговице на ра оболочку передней камеры глаза.Recipient rats are put on their eyes a drop of a 0.1% solution of atropine and a drop of a 0.5% solution of novokan Gd. The transplantation is carried out with ether anesthesia. Using a tuberculin syringe with a screw feed, on which a glass tip is worn (inside diameter 0.8 (l, 0 mm), the graft is taken from the Petri dish and the sheath of the anterior chamber is inserted through the incision in the cornea.
После операции крыс содержат на стандартной диете, разработаиной дл лабо- раторных животных. Раз в неделю у них определ ют содержание глюкозы в моче. При трансплантации в переднюю камеру глаз после определеиного срока глаз с трансплантатом энуклерируют и тестирую уроЭень глюкозы. По окончании опытов провод т гистологический анализ трансплантата с окраской по Маллори и геиотоксилин эозином.After the operation, the rats are kept on a standard diet developed for laboratory animals. Once a week, they determine the content of glucose in the urine. When transplanted into the anterior chamber of the eye after a definite period of time, the eyes with the graft are enucleated and I test the glucose level. At the end of the experiments, histological analysis of the graft stained with Mallory and geiotoxilin eosin was performed.
Прк - визуальном наблюдении за трансплантатами в передней камере глаза отмеPrk - visual observation of grafts in the anterior chamber of the eye
чают, 4fo через 2-3 дн к ним иачинают прорастать сосуды. Их количество н диаметр увеличиваетс приблизительно в течение 10-15 дней, н через 2 недели некоторые трансплантаты полностью скрываютс под сосудами.При гистологическом анализеso, 4fo after 2-3 days to them the vessels begin to germinate. Their number n diameter increases approximately within 10-15 days, and after 2 weeks some transplants are completely hidden under the vessels. During histological analysis
OO
5 five
s s
0 50 5
О 35 About 35
4040
трансплантатов через 6-20 недель после .трансплантации в них обнаруживают ост- ровковые клетки,вк.точенные в соединительно-тканную строму.grafts 6–20 weeks after transplantation in them are islet cells, found in the connective stroma.
Из 13 крыс с трансплантированной тканью поджелудочной железы в переднюю камеру глаза у 8 наблюдали полную ком пенсацию диабета, у 3 она была частичной и у 2 количество глюкозы оставалось на прежнем уровне. Компенсаци обычно начиналась на 2 неделе после трансплантации. На третьей неделе количество глюкозы в моче снижалось до нормы и сохран лось на этом уровне в течение 20-23 недель ( максимальный период наблюдени ).Of 13 rats with transplanted pancreatic tissue in the anterior chamber of the eye, 8 showed complete compensation of diabetes, in 3 it was partial and in 2 the amount of glucose remained at the same level. Compensation usually began at week 2 after transplantation. On the third week, the amount of glucose in the urine decreased to normal and remained at this level for 20-23 weeks (maximum observation period).
После энуклеации глаза с трансплантатом у крыс снова повышалось содержание глюкозы в моче.After enucleation of the eye with a transplant in rats, the content of glucose in the urine increased again.
Использование способа моделировани компенсации сахарного диабета позвол ет сохранить компенсацию диабета на прот жении всего периода наблюдени (23 недели ) без призиаков иммунологической реакци отторжени со стороны реципиента. Это обусловлено тем, что передн камера глёза относитс к иммунопривилегирован ным област м организма. Оиа отделена от иммунной системы гематоофтальмологиче- ским барьером, через который не проникают аититела, что допускает возможность длительного приживлени тpaнcплaнtaтoв без отторжени .Using the method of simulating the compensation of diabetes mellitus allows you to maintain compensation for diabetes throughout the entire observation period (23 weeks) without any signs of immunological rejection by the recipient. This is due to the fact that the anterior chamber of the eye belongs to immunoprivileged areas of the body. Oia is separated from the immune system by the hematophthalmologic barrier through which the antibodies do not penetrate, which allows for the possibility of prolonged survival of the transplant without rejection.
В процессе приживлени транспла татд формируетс специфический гистогематиче- ский барьер, проницаемый дл инсулина. Наблюдаетс стойкий клинический эффект компенсации диабета, в процессе которого количество глюкозы в моче устанавливаетс на нормальном уровне.In the process of engraftment of tatd transplants, a specific histohematogenous barrier permeable to insulin is formed. A persistent clinical effect of diabetes compensation is observed, during which the amount of glucose in the urine is established at a normal level.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823474670A SU1369039A1 (en) | 1982-07-16 | 1982-07-16 | Method of simulating compensation of diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU823474670A SU1369039A1 (en) | 1982-07-16 | 1982-07-16 | Method of simulating compensation of diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1369039A1 true SU1369039A1 (en) | 1988-09-07 |
Family
ID=21023797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823474670A SU1369039A1 (en) | 1982-07-16 | 1982-07-16 | Method of simulating compensation of diabetes |
Country Status (1)
| Country | Link |
|---|---|
| SU (1) | SU1369039A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009027106A3 (en) * | 2007-08-31 | 2009-07-23 | Biocrine Ab | Non-invasive in vivo imaging and methods for treating type i diabetes |
-
1982
- 1982-07-16 SU SU823474670A patent/SU1369039A1/en active
Non-Patent Citations (1)
| Title |
|---|
| Gonet А. Е. е1 1 , J. Diabetologia, . , 1965. * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009027106A3 (en) * | 2007-08-31 | 2009-07-23 | Biocrine Ab | Non-invasive in vivo imaging and methods for treating type i diabetes |
| JP2011256202A (en) * | 2007-08-31 | 2011-12-22 | Biocrine Ab | Method of manufacturing implant for enhancing insulin generation in patient with type i diabetes |
| EP2441462A1 (en) * | 2007-08-31 | 2012-04-18 | BioCrine AB | Method for treating type I diabetes |
| US9463205B2 (en) | 2007-08-31 | 2016-10-11 | Biocrine Ab | Non-invasive in vivo imaging and methods for treating type I diabetes |
| US10207012B2 (en) | 2007-08-31 | 2019-02-19 | Biocrine Ab | Non-invasive in vivo imaging and methods for treating type I diabetes |
| US10493108B2 (en) | 2007-08-31 | 2019-12-03 | Biocrine Ab | Non-invasive in vivo imaging and methods for treating diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chick et al. | A transplantable insulinoma in the rat. | |
| Bowen et al. | Successful allotransplantation of mouse pancreatic islets to nonimmunosuppressed recipients | |
| JP3621106B2 (en) | In vitro culture of functional islets of Langerhans and its in vivo use | |
| US5679565A (en) | Method of preserving pancreatic islets | |
| Woodruff et al. | The transplantation of normal tissues: with special reference to auto-and homotransplants of thyroid and spleen in the anterior chamber of the eye, and subcutaneously, in guinea-pigs | |
| Deng et al. | Urine-derived stem cells facilitate endogenous spermatogenesis restoration of busulfan-induced nonobstructive azoospermic mice by paracrine exosomes | |
| Nayar | Studies on the neurosecretory system of Iphita limbata stal: Part V. Probable endocrine basis of oviposition in the female insect | |
| RU2160112C1 (en) | Method for producing cellular transplant from fetus tissues | |
| Smyth et al. | Further analysis of the factors controlling strobilization, differentiation, and maturation of Echinococcus granulosus in vitro | |
| Smith et al. | Some in vitro studies on rabbit corneal tissue | |
| Weber et al. | Xenotransplantation of piscine islets into hyperglycemic rats | |
| Babel et al. | Experimental research with corneal heterografts | |
| Rothstein | Experimental techniques for investigation of the amphibian lens epithelium | |
| Talmage et al. | Effect of oxygen pressure during culture on survival of mouse thyroid allografts | |
| Joris et al. | Cell-to-cell herniae in the arterial wall. I. The pathogenesis of vacuoles in the normal media | |
| Sørensen et al. | Intracephalic transplants of freeze‐Stored rat hippocampal tissue | |
| CN110857434A (en) | Methods and compositions for promoting cell growth and tissue repair | |
| CN109078021A (en) | A kind of injection of the excretion of mescenchymal stem cell containing endometrium body | |
| SU1369039A1 (en) | Method of simulating compensation of diabetes | |
| TWI389696B (en) | Artificial kidney precursor and process for producing the same | |
| Berman et al. | The influence of the flow of detergent and donor characteristics on the extracellular matrix composition after human pancreas decellularization | |
| Jørgensen et al. | Effect of extirpation of median eminence on function of pars distalis of the hypophysis in the toad Bufo bufo (L.) | |
| CN102480935B (en) | Method Of Processing Allograft Skin For Transplantation, And Cryopreserved Allograft Skin Produced Thereby | |
| Dudley | Insulin from the cod fish: the direct application of picric acid to the islet tissue | |
| RU2135193C1 (en) | Method of preparing material containing pancreatic beta-cells for transplantation in diabetic patients utilizing cell migration phenomenon, material containing pancreatic beta-cells for transplantation in diabetic patients, and method of treating diabetes mellitus by transplantation method |